{"filing":{"accession_number":"0001140361-26-026031","cik":"0001133416","ticker":"GALT","company_name":"GALECTIN THERAPEUTICS INC","form":"8-K","filing_date":"2026-06-23","report_date":null,"primary_document":"ef20076593_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1133416/000114036126026031/ef20076593_8k.htm"},"events":[{"id":12999,"run_id":11539,"accession_number":"0001140361-26-026031","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Galectin announced positive feedback from an FDA Type C meeting regarding belapectin's development pathway for MASH cirrhosis, including FDA agreement on the primary endpoint (composite liver outcome including large esophageal varices), central endoscopy review methodology, and regulatory path toward full approval. This is a material regulatory milestone that clarifies the clinical development strategy and regulatory framework for the company's lead drug candidate, but does not fit the specific categories of earnings release, M\u0026A activity, or other named event types. It is clearly operational/strategic in nature—a significant development program milestone with regulatory alignment.","company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","filing_date":"2026-06-23","form":"8-K","submitted_at":null,"items":[{"id":10013,"accession_number":"0001140361-26-026031","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Galectin announced positive feedback from an FDA Type C meeting regarding belapectin's development pathway for MASH cirrhosis, including FDA agreement on the primary endpoint (composite liver outcome including large esophageal varices), central endoscopy review methodology, and regulatory path toward full approval. This is a material regulatory milestone that clarifies the clinical development strategy and regulatory framework for the company's lead drug candidate, but does not fit the specific categories of earnings release, M\u0026A activity, or other named event types. It is clearly operational/strategic in nature—a significant development program milestone with regulatory alignment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T11:52:38.875732+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10013,"accession_number":"0001140361-26-026031","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Galectin announced positive feedback from an FDA Type C meeting regarding belapectin's development pathway for MASH cirrhosis, including FDA agreement on the primary endpoint (composite liver outcome including large esophageal varices), central endoscopy review methodology, and regulatory path toward full approval. This is a material regulatory milestone that clarifies the clinical development strategy and regulatory framework for the company's lead drug candidate, but does not fit the specific categories of earnings release, M\u0026A activity, or other named event types. It is clearly operational/strategic in nature—a significant development program milestone with regulatory alignment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T11:52:38.875732+00:00","company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","filing_date":"2026-06-23"}]}